Alumis (NASDAQ:ALMS) Director Buys 588,235 Shares

Alumis Inc. (NASDAQ:ALMS) Director Srinivas Akkaraju bought 588,235 shares of the stock in a transaction dated Friday, January 9th. The stock was bought at an average price of $17.00 per share, with a total value of $9,999,995.00. Following the acquisition, the director owned 1,853,488 shares in the company, valued at approximately $31,509,296. This represents a 46.49% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Srinivas Akkaraju also recently made the following trade(s):

• On Friday, December 5th, Srinivas Akkaraju bought 186,377 shares of Alumis stock. The stock was purchased at an average cost of $9.84 per share, with a total value of $1,833,949.68.
• On Thursday, December 4th, Srinivas Akkaraju bought 66,027 shares of Alumis stock. The shares were acquired at an average price of $8.18 per share, for a total transaction of $540,100.86.
• On Wednesday, December 3rd, Srinivas Akkaraju purchased 100,000 shares of Alumis stock. The shares were bought at an average cost of $7.75 per share, for a total transaction of $775,000.00.
• On Tuesday, December 2nd, Srinivas Akkaraju acquired 96,000 shares of Alumis stock. The stock was purchased at an average price of $7.55 per share, for a total transaction of $724,800.00.
• On Monday, December 1st, Srinivas Akkaraju acquired 86,350 shares of Alumis stock. The stock was purchased at an average cost of $7.46 per share, for a total transaction of $644,171.00.
• On Friday, November 28th, Srinivas Akkaraju bought 38,702 shares of Alumis stock. The shares were acquired at an average price of $7.64 per share, for a total transaction of $295,683.28.
• On Wednesday, November 26th, Srinivas Akkaraju purchased 48,537 shares of Alumis stock. The stock was bought at an average price of $7.64 per share, with a total value of $370,822.68.
• On Thursday, November 20th, Srinivas Akkaraju acquired 125,743 shares of Alumis stock. The stock was purchased at an average cost of $7.20 per share, with a total value of $905,349.60.
• On Wednesday, November 19th, Srinivas Akkaraju bought 137,772 shares of Alumis stock. The stock was purchased at an average cost of $6.56 per share, for a total transaction of $903,784.32.
• On Tuesday, November 18th, Srinivas Akkaraju purchased 102,652 shares of Alumis stock. The shares were purchased at an average cost of $6.05 per share, with a total value of $621,044.60.

Alumis Stock Performance

NASDAQ ALMS traded up $1.02 during trading hours on Tuesday, reaching $22.11. The company’s stock had a trading volume of 4,660,878 shares, compared to its average volume of 12,771,338. The company’s 50-day moving average is $9.54 and its two-hundred day moving average is $6.08. Alumis Inc. has a fifty-two week low of $2.76 and a fifty-two week high of $23.00. The stock has a market cap of $2.31 billion, a PE ratio of -5.46 and a beta of -2.09.

Alumis (NASDAQ:ALMS) last announced its quarterly earnings results on Thursday, November 13th. The company reported ($1.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.92) by ($0.14). The business had revenue of $2.07 million for the quarter, compared to the consensus estimate of $3.14 million. Equities analysts expect that Alumis Inc. will post -8.51 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on ALMS shares. Morgan Stanley boosted their price target on Alumis from $22.00 to $33.00 and gave the stock an “overweight” rating in a report on Wednesday, January 7th. HC Wainwright reissued a “buy” rating and issued a $40.00 target price (up previously from $20.00) on shares of Alumis in a research note on Friday. Wells Fargo & Company upped their target price on shares of Alumis from $17.00 to $39.00 and gave the company an “overweight” rating in a report on Tuesday, January 6th. Wall Street Zen raised shares of Alumis from a “sell” rating to a “hold” rating in a research note on Saturday, December 6th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Alumis in a research note on Monday, December 29th. Nine research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $37.67.

Trending Headlines about Alumis

Here are the key news stories impacting Alumis this week:

• Positive Sentiment: Major insider/investor purchase — Foresite (and director James Tananbaum) bought 411,764 shares at an average of $17.00 (≈$7.0M), increasing their stake by 7.78% to 5,702,536 shares; large insider buys often signal confidence and can drive short‑term buying interest. Insider SEC Filing
• Positive Sentiment: Media coverage amplifying the buy — multiple outlets (Investing.com, InsiderTrades, MarketBeat) picked up the trade, increasing visibility and likely contributing to upward price momentum as retail and momentum traders react. Investing.com: Foresite buys ALMS
• Neutral Sentiment: Analyst coverage is favorable — recent research notes (UBS, Oppenheimer, Guggenheim, Wells Fargo, Citi) show multiple “outperform/buy” ratings and raised price targets (consensus target cited ~ $37.67). Positive analyst commentary supports sentiment but valuation and clinical execution remain key. MarketBeat: ALMS coverage
• Neutral Sentiment: Institutional position moves — various institutional holders (Vanguard, Samsara Biocapital, Trium Capital, Orbimed) have recently adjusted stakes; these shifts can provide liquidity and longer-term support but do not guarantee near-term price direction.
• Negative Sentiment: Underlying fundamentals and recent results are still weak — the company reported an earnings miss (Q3: EPS -$1.06 vs. -$0.92 est.; revenue $2.07M vs. $3.14M) and analysts still expect negative EPS for the year, so upside depends on clinical progress and execution rather than current revenue. MarketBeat: ALMS earnings and analyst notes

Institutional Investors Weigh In On Alumis

Large investors have recently made changes to their positions in the business. Russell Investments Group Ltd. raised its stake in shares of Alumis by 320.9% in the 3rd quarter. Russell Investments Group Ltd. now owns 6,419 shares of the company’s stock valued at $26,000 after acquiring an additional 4,894 shares during the period. Kera Capital Partners Inc. purchased a new position in Alumis in the second quarter valued at about $32,000. Police & Firemen s Retirement System of New Jersey lifted its stake in shares of Alumis by 199.7% during the second quarter. Police & Firemen s Retirement System of New Jersey now owns 10,753 shares of the company’s stock worth $32,000 after purchasing an additional 7,165 shares in the last quarter. New York State Common Retirement Fund boosted its position in shares of Alumis by 173.7% in the second quarter. New York State Common Retirement Fund now owns 11,767 shares of the company’s stock worth $35,000 after buying an additional 7,467 shares during the period. Finally, Western Wealth Management LLC acquired a new stake in shares of Alumis in the second quarter valued at about $36,000.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.